Literature DB >> 23186257

Structure-activity relationships for α-calcitonin gene-related peptide.

Harriet A Watkins1, Dan L Rathbone, James Barwell, Debbie L Hay, David R Poyner.   

Abstract

UNLABELLED: Calcitonin gene-related peptide (CGRP) is a member of the calcitonin (CT) family of peptides. It is a widely distributed neuropeptide implicated in conditions such as neurogenic inflammation. With other members of the CT family, it shares an N-terminal disulphide-bonded ring which is essential for biological activity, an area of potential α-helix, and a C-terminal amide. CGRP binds to the calcitonin receptor-like receptor (CLR) in complex with receptor activity-modifying protein 1 (RAMP1), a member of the family B (or secretin-like) GPCRs. It can also activate other CLR or calcitonin-receptor/RAMP complexes. This 37 amino acid peptide comprises the N-terminal ring that is required for receptor activation (residues 1-7); an α-helix (residues 8-18), a region incorporating a β-bend (residues 19-26) and the C-terminal portion (residues 27-37), that is characterized by bends between residues 28-30 and 33-34. A few residues have been identified that seem to make major contributions to receptor binding and activation, with a larger number contributing either to minor interactions (which collectively may be significant), or to maintaining the conformation of the bound peptide. It is not clear if CGRP follows the pattern of other family B GPCRs in binding largely as an α-helix. LINKED ARTICLES: This article is part of a themed section on Neuropeptides. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.170.issue-7.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Keywords:  CGRP; GPCR; RAMP; adrenomedullin; amylin; calcitonin; domain; helix cap; juxtamembrane domain; receptor activation; receptor activity-modifying protein

Mesh:

Substances:

Year:  2013        PMID: 23186257      PMCID: PMC3838678          DOI: 10.1111/bph.12072

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  76 in total

1.  Conformation of a peptide ligand bound to its G-protein coupled receptor.

Authors:  H Inooka; T Ohtaki; O Kitahara; T Ikegami; S Endo; C Kitada; K Ogi; H Onda; M Fujino; M Shirakawa
Journal:  Nat Struct Biol       Date:  2001-02

Review 2.  International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors.

Authors:  David R Poyner; Patrick M Sexton; Ian Marshall; David M Smith; Remi Quirion; Walter Born; Roman Muff; Jan A Fischer; Steven M Foord
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

Review 3.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains.

Authors:  K A Carpenter; R Schmidt; B von Mentzer; U Haglund; E Roberts; C Walpole
Journal:  Biochemistry       Date:  2001-07-27       Impact factor: 3.162

5.  Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists.

Authors:  John J Mallee; Christopher A Salvatore; Beatrice LeBourdelles; Kevin R Oliver; Jenny Longmore; Kenneth S Koblan; Stefanie A Kane
Journal:  J Biol Chem       Date:  2002-02-14       Impact factor: 5.157

6.  Minimization of parathyroid hormone. Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor.

Authors:  M Shimizu; J T Potts; T J Gardella
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

Review 7.  Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs?

Authors:  James Barwell; Joseph J Gingell; Harriet A Watkins; Julia K Archbold; David R Poyner; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

8.  Bioactive beta-bend structures for the antagonist halpha CGRP(8 - 37) at the CGRP(1) receptor of the rat pulmonary artery.

Authors:  F M Wisskirchen; P M Doyle; S L Gough; C J Harris; I Marshall
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 9.  CGRP receptor antagonists: an expanding drug class for acute migraine?

Authors:  Andrea Negro; Luana Lionetto; Maurizio Simmaco; Paolo Martelletti
Journal:  Expert Opin Investig Drugs       Date:  2012-04-19       Impact factor: 6.206

10.  A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells.

Authors:  Debbie L Hay; Stephen G Howitt; Alex C Conner; Henri Doods; Marcus Schindler; David R Poyner
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

View more
  27 in total

1.  Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins.

Authors:  Heather E Moad; Augen A Pioszak
Journal:  Protein Sci       Date:  2013-10-19       Impact factor: 6.725

2.  The background to this themed issue on neuropeptides.

Authors:  Julie Keeble
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 3.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 4.  Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.

Authors:  Debbie L Hay; Michael L Garelja; David R Poyner; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-11-28       Impact factor: 8.739

5.  Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors.

Authors:  Erica R Hendrikse; Lydia P Liew; Rebekah L Bower; Muriel Bonnet; Muhammad A Jamaluddin; Nicole Prodan; Keith D Richards; Christopher S Walker; Garry Pairaudeau; David M Smith; Roxana-Maria Rujan; Risha Sudra; Christopher A Reynolds; Jason M Booe; Augen A Pioszak; Jack U Flanagan; Michael P Hay; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-12

6.  Calcitonin Gene-Related Peptide Regulates Cardiomyocyte Survival through Regulation of Oxidative Stress by PI3K/Akt and MAPK Signaling Pathways.

Authors:  Nsini A Umoh; Robin K Walker; Richard M Millis; Mustafa Al-Rubaiee; Pandu R Gangula; Georges E Haddad
Journal:  Ann Clin Exp Hypertens       Date:  2014-01

Review 7.  Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.

Authors:  Rebekah L Bower; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2016-05-18       Impact factor: 8.739

8.  Slow Internal Dynamics and Charge Expansion in the Disordered Protein CGRP: A Comparison with Amylin.

Authors:  Sara M Sizemore; Stephanie M Cope; Anindya Roy; Giovanna Ghirlanda; Sara M Vaiana
Journal:  Biophys J       Date:  2015-09-01       Impact factor: 4.033

Review 9.  Role of calcitonin gene-related peptide in energy metabolism.

Authors:  William Gustavo Lima; Gleuber Henrique Marques-Oliveira; Thaís Marques da Silva; Valéria Ernestânia Chaves
Journal:  Endocrine       Date:  2017-09-07       Impact factor: 3.633

Review 10.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.